Patents. Law. Pharma.
917.609.2296
BLOG
What is Gilead's exposure from GSK's patent lawsuit against Biktarvy®, Gilead's new integrase inhibitor HIV therapy?
Gilead’s new HIV drug, Biktarvy®, has received FDA approval. Almost immediately, Gilead was hit with a patent-infringement lawsuit by ViiV Healthcare, which is owned by GSK, along with Pfizer and Shionogi. What is Gilead’s exposure?